PRINCETON, N.J. and HANGZHOU, China, December 29, 2025 -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company.

Data showed encouraging results in patients with higher CLDN18.2 expression, regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months.

Transcenta holds the exclusive rights to develop and commercialize ozekibart (INBRX-109) in mainland China, Hong Kong SAR, Macau SAR, and Taiwan region under a license agreement executed through HJB (Hangzhou) Co., Ltd * (杭州奕安济世生物药业有限公司) (“HJB”), a wholly owned subsidiary of Transcenta Holding.

Mr. Marciniak will serve as a member of the senior management team and lead the company's enterprise-wide capital fundraising strategy, as well as its efforts to establish and maintain mutually beneficial relationships with key stakeholders to drive growth and position the company as a global leader in biopharmaceutical innovation.

These favorable outcomes deepen our commitment to advance this treatment through accelerated clinical trials, with the ultimate goal of making it available to patients globally.